sellWeak cluster of 210b5-1 plan
Sonja Nelson sold $125k of AMAM
Chief Financial Officer at Ambrx Biopharma, Inc.. 12,778 shares at an average of $9.82, traded Oct 27, 2023, filed Oct 31, 2023.
Warning score
21Value
$125k
12,778 shares
Holdings after
130,079
-9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +11Trade size$125k at market
- 0Share of holdings soldSold 8.9% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-056944, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 27, 2023 | SOpen-market sale Common Stock10b5-1 | -12,778 | $9.82 | $125k | 130,079 | Oct 31, 2023 |
Related signals
Other insiders at Ambrx Biopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Ambrx Biopharma, Inc. | Daniel J. O'Connor President and CEO | $491k 50,012 shares | -13% | |
| 30Weak | AMAMbuy Ambrx Biopharma, Inc. | Cormorant Asset Management, LP owner | $9.1M 1,307,311 shares | +13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.